Leading Physician and Business Executive is Added to the Senior Scientific and Management Advisory Group.
Richmond, Va., January 29, 2018 – ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, announces a key addition to its Executive and Scientific Team.read more
Alliance with China-based diagnostic company to support joint clinical studies and prepare for diagnostic product introduction in Chinese markets
Richmond, VA., July 10, 2017 – ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, and Kindstar Global Co., Ltd., a specialty clinical testing company based in Wuhan, China with locations throughout mainland China, have forged a partnership involving shared clinical studies and the launch of ImmunArray’s lupus rule-out test in China as the initial product offering.read more
Virginia Bio Companies AMPEL BioSolutions And ImmunArray Announce Collaboration To Advance Treatment Of Lupus On World Lupus Day
May 10, 2017, (World Lupus Day) Charlottesville and Richmond, VA – AMPEL BioSolutions, a leading biomedical research consultation firm and clinical operations company in Charlottesville, Virginia, and ImmunArray, Ltd., a molecular diagnostic company co-headquartered in Rehovot, Israel and Richmond, Virginia are pleased to announce the LuPUS (Lupus Profiling and AUtoantibody Standardization) Project, a strategic partnership that seeks to inform the development of new tools to diagnose and treat lupus patients.
Quanterix gains access to ImmunArray brain injury biomarker portfolio and ImmunArray gains access to Quanterix state of the art digital biomarker technologyread more
Molecular diagnostic company’s research into blood-based diagnosis of traumatic brain injury presented at national conferences
Richmond, Va., July 18, 2016 – Clinical research into ways in which blood-based biomarkers can provide precise and timely diagnosis of traumatic brain injury (TBI) is leading to encouraging results, with some studies resulting in a diagnosis with more than 95 percent sensitivity and specificity.read more